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Summary of ICB IV
Workshop 3:
Business Cases for
Integrated and
Continuous
Biomanufacturing

Moderators: Jessica Molek, GSK
Daisie Ogawa, Boehringer Ingelheim
Integrated and Continuous Bioprocessing IV
Cape Cod, Massachusetts. October 9, 2019

Utilization of traditional batch processes is so entrenched in the biopharmaceutical
production landscape that transitioning to a new approach, no matter how efficient
or productive, is challenging. Integrated, continuous manufacturing (CM) promises
higher per-bioreactor vessel productivity, smaller downstream footprints, and more

Workshop 3
Abstract

consistent product quality than batch processing. However, realization of these
benefits depends greatly on the scenario at hand and the proposed manufacturing
strategy. A compelling business case must be presented in order to consider making
the transition to CM from the traditional manufacturing approach. The degree of
process integration, the target scale and facility vision toward automation, as well as
the strategy toward implementation with respect to portfolio maturity are key actors
to consider. This workshop will explore some of these key strategic factors and how
they influence the business case for CM.

 Workshop Welcome
 Introductions of Co-chairs
 Pre-workshop Survey
 Review of survey questions 1-3

Agenda

 Reading of workshop prompts 1-5
 20 minutes of break-out discussions
 2 tables for each of prompts 1-4, no takers for prompt 5

 50 minutes of group discussion (10 minutes per prompt)
 Wrap up and thanks

Pre-workshop
Survey
Questions

1.

Is your company considering continuous manufacturing for early stage or late
stage programs?
a.
early
b. late
c.
both

2.

How far along is your company in adopting Continuous Manufacturing?
a.
not pursuing at all
b.
very early- ie paper-based thought experiment
c.
early- hands-on lab-based process development
d.
mid- preparing for clinical
e.
mid/late- clinical mfg has occurred
f.
commercial

3.

Do you foresee GMP manufacturing using a continuous manufacturing vendorsupplied platform or a custom, in-house developed platform?
a.
Vendor(s)
b. In-house

4.

What do you feel is the single biggest benefit of continuous?

5.

What do you feel is the single biggest hurdle for implementation of
continuous?

Current State
13

7

0

Late stage vs Early stage

13

Survey Answers:
By the Numbers
62 Participants in
Attendance

39
24

28
Not Pursuing At All

Very Early (paper based thought)

Early (hands on - lab based)

Mid (prepare for clinical)

Mid/Late (completed clinical)

Commercial

Platform
37
63
Vendor Supplied
In House

15

62

Early

Late

Both

Benefits

Risks

Prompts

1.

What do you think are the key business drivers currently influencing the
biopharmaceutical industry: footprint reduction, speed to market, speed of
production, speed of expansion, improved product quality, reduced capex
or opex, other? In what way does continuous manufacturing meet the
challenges associated with these business drivers?

2.

What is the ideal level of integration for unit operations? Where are the
biggest benefits to integration (eg linking perfusion bioreactor to capture
columns)? What might be some of the main business case arguments
which inform these decisions?

3.

What are the major risks for a business to add capability of integrated
continuous processing: replace/retrofitting of existing facilities, investment
in greenfield, regulatory concerns, technology development, supply chain
security, etc.

4.

What stage of a program is best suited for implementation of continuous
processing (early, late, post approval) and why? Does the degree of
integration change based on the time of implementation in the product
lifecycle?

5.

Batch definition and associated analytical testing strategy has a major
impact on the overall cost, speed to market, and supply chain strategy.
How should the definition and strategy be defined to balance the benefits
and risks associated with continuous manufacturing?

 Reduction in Cost of Goods/Risk
•
•
•
•

 Agility
•
•
•

Prompt 1What are the
key business
drivers for ICB?

not over-producing at FB large scale
for low-demand modalities
Reducing CapEx/OpEx (especially by reducing size of facility)
Reducing $/m2 or $/yr vs $/g
CMO perspective
Single use
Access (less complex Supply Chain, more distributed manufacturing)

 Modality-specific drivers

• bsAB- stability
• LV- stability
• mAb- high dose requirements, large patient populations. Higher titer is advantage here

 Cost pressure for healthcare
 Improved and/or more consistent product quality, enabled by PAT
 Alleviate capacity constraints of network
 Streamline control strategy (scale-out vs scale-up no change in process)
 At-scale development
 De-bottlenecking DSP
 Demonstrated benefits in other industries (auto, semiconductor, etc)
 Many points refer to extensive implementation of continuous, continuous/connected
Upstream, and/or downstream may be more easily quantified

 The problem being solved by integration often defines level of
integration, each company will dictate the extent of integration for
themselves. May be based on stage at which continuous is first used
 Vial to vial (ideal)– lots of back-and-forth discussion on this point,
generally agreed that it really depends on the molecule and indication

Prompt 2Ideal level of
Integration?
Biggest
Benefits?

 Including analytics
 Challenge – if have different Drug Product presentation could be
different
 API Shelf time is now not applicable so inventory only controlled on DP
Stability






Process until stable intermediate for mAbs
Reduces affinity capture resin costs
Most beneficial for a new facility or a new process
Most beneficial steps to connect:

 Perfusion- capture (especially from an intensified perfusion bioreactor)
 No harvest, no centrifuge or filters







Buffer prep from concentrate
(stable hold points) neutralized VI
Automated sampling
Analytics on the floor
Polishing-rest

 Capex

 Retrofitting: costs and
downtime
 Capex concerns at outlay to
convert

 Equipment

Prompt 3What are the
major risks of
adding ICB
capability?

 Familiarity of new
equipment and processes
 Immaturity of technology
 Lack of standardization of
equipment

 Need to develop relationships
with new vendors
 Nonstandardized supply
chain components
 Management of inventory
 Highly reliant on single
sources components

 Supplying both batch and ICB
with enough production to fill
all facilities.

 Having to decide which type
of facility to develop toward
– two parallel tracks?
 Dilution of resources to
develop processes

 Regulatory Risks





Control Strategy
Process Validation
Comparability (late stage)
Bioburden control

 Highly automated

 How to handle deviations
 How to handle pauses when
running in constant flow

 Optimization for changing
portfolio

 Quantification of benefits
 Product / pipeline
requirements
 Importance of Cost reduction

 Automation

 Requires platform from the
beginning to be automated
 Automation expertise
required
 Lack of standardization
exists
 Choice of CMOs becomes
more limited

 Implementation during product lifecycle is based on portfolio
distribution and capacity availability

Prompt 4What process
stage is best
for ICB? Is
integration
extent based
on process
stage?

 Why Early Phase






Decrease comparability risk and will allow program to develop over time
FB to perfusion transition during late stage could be challenge
Many technologies well established, can be adopted early
Regulatory expectation still unknown
Attrition in the clinic can delay tech introduction

 Why Late Phase

 Takes speed to clinic off critical path
 Ability to achieve a lower additional capex cost

 General Challenges:

 Steady State Perfusion can be difficult to achieve, increase risk of
failures/ interruptions, could cause bigger timeline delays
 Infrastructure for ICB takes time to develop
 Shorter dynamic perfusion might be faster for timeline to clinic, but may
be hard to transition to steady state perfusion during late stage
development
 Novel modalities may be more difficult to express/ purify

 Batch definition was not problematic

#5 Batch
definition

 Batch could be defined in multiple different ways, but based on
company need
 Sample load could be decreased if deemed to be the best way to
define a batch

 Flexibility of batch is available
 More details to be provided in ICHQ13

 No “one size fits all” solution, business case highly dependent on
individual company needs

Entire
Workshop
Summary

 Benefits depend on portfolio (stage and modality focus) and
current capacity/capabilities
 Cost of goods (including CapEx, $/g, g/m2) reduction by ICB was
brought up repeatedly, by multiple companies as a key driver
 Business cases have been successful – progression over two years
on implementation (including GMP implementation session)

